Columbus Children's Foundation

What Columbus Children's Foundation does

Columbus Children's Foundation is a 501(c)(3) nonprofit founded in 2018 and headquartered in Chapel Hill, North Carolina, with a 1-10 person operating team. Its mission is to accelerate access to gene therapy for children with ultra-rare neurodegenerative genetic diseases whose patient populations are too small to attract commercial drug development. The foundation was co-founded by Columbus Venture Partners, Asklepios Biopharmaceutical (AskBio), and Viralgen Vector Core, and shares a European sister organization, Fundación Columbus, established in Valencia, Spain in 2017.

The foundation's core technology is AAV-based gene therapy delivered directly to the brain, a method pioneered by co-founder and Chief Medical Officer Krystof Bankiewicz. The clinical pipeline includes AADC deficiency (in clinical trials), SPG50, MPS III/Sanfilippo Type C, Duchenne muscular dystrophy (in manufacturing), and pre-clinical programs for Niemann-Pick A and C. Key programs include Target10 (a 2025 initiative with Viralgen to develop ten gene therapy treatments for ten rare diseases in ten years), CCF Open-Source (publishing program research and clinical data for the gene therapy community), and Gene Flight (covering travel and lodging for families participating in clinical trials at Brodno Hospital in Warsaw or US centers). Twenty-five or more children have been treated with AADC gene therapy to date.

The foundation is funded through a tiered philanthropic model: Founding Trustees ($1,000,000 multi-year commitments), Rare Child Champions ($150,000-$500,000 annually), Gene Flight Sponsors ($25,000), and Discovery Team sponsors ($25,000-$100,000). Supporting revenue comes from branded merchandise (RARE and HOPE bracelets at $40, UNRL RARE hats at $35, produced with jewelry partner Realia by Jen and apparel partner UNRL), corporate matching gift programs, and awareness-event fundraising including benefit concerts, the Rocket Mortgage Classic Birdies for Charity program, and a 2025 Real Sociedad vs. Bayer Leverkusen charity soccer match. The foundation markets primarily through social media hashtag campaigns (#ShareYourRare, #AADCmiles, #RareYou), Rare Disease Day activations, and email newsletters. Leadership is concentrated among co-founders Sheila Mikhail (Executive Director; former CEO and co-founder of AskBio, $4B Bayer acquisition), R. Jude Samulski (Chief Science Officer; 40 years of AAV research, 300+ patents, founder of UNC Gene Therapy Center), and Krystof Bankiewicz (Chief Medical Officer; Professor of Neurosurgery at Ohio State University).

Name

Columbus Children's Foundation

Legal name

Columbus Children's Foundation

Website

https://columbuschildren.org

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Columbus Children's Foundation is a 501(c)(3) nonprofit that accelerates access to AAV gene therapy for children with ultra-rare neurodegenerative genetic diseases, funding clinical programs, manufacturing partnerships, and patient travel support through philanthropic donations and awareness events.

Ownership category

akta.pro rank

Product category

Nonprofit Rare Disease Gene Therapy Foundation

NAICS

Voluntary Health Organizations (813212), Scientific Research and Development Services (5417), Other Individual and Family Services (624190)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurology/CNS Gene Therapies (HLAAACAH), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Rare disease gene therapy
• Pediatric neurodegenerative disorders
• AAV vector manufacturing
• Ultra-rare disease foundation
• Charitable clinical research

Headquarters

HQ city

Chapel Hill

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Donations and Charitable Contributions: The primary revenue stream comes from donations from individuals, corporations, and philanthropic organizations. The foundation offers various giving levels including Founding Trustees ($1 million commitment), Rare Child Champions ($150,000-$500,000 annually), Gene Flight Sponsorship ($25,000), and Discovery Team ($25,000-$100,000).
2. Merchandise Sales: Sale of branded merchandise including bracelets and hats to raise awareness and funds. Products include RARE bracelets ($40), HOPE bracelets ($40), and UNRL RARE hats ($35).

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Columbus Children's Foundation is a 501(c)(3) nonprofit foundation that accelerates equitable access to AAV-based gene therapy treatments for children with ultra-rare neurodegenerative genetic diseases such as AADC deficiency, SPG50, Niemann-Pick disease types A and C, Sanfilippo Type C, and Duchenne muscular dystrophy. The foundation funds translational research, secures discounted AAV vector manufacturing through Viralgen Vector Core, operates the Gene Flight Program for patient travel/lodging, and shares program data openly through the CCF Open-Source initiative.

Product overview

Columbus Children's Foundation operates as a non-profit focused on accelerating access to gene therapy for children with ultra-rare genetic diseases. The core offerings consist of gene therapy programs (including the Target10 Program initiative to develop 10 treatments for 10 diseases in 10 years), the CCF Open-Source data initiative for sharing research publicly, and support services including the Gene Flight Program (travel/lodging assistance) and Family Support Program. The foundation also sells merchandise including awareness bracelets (RARE and HOPE bracelets in collaboration with Realia by Jen) and UNRL branded hats, with proceeds supporting the Rare Fund.

Differentiator

Problem solved

Functional benefit

Brands

• CCF Open-Source: CCF initiative that puts program research and clinical data into the public domain where possible, building a shared knowledge base accessible to the gene therapy research community.

Products and services

• Gene Therapy Programs Core translational AAV gene therapy programs for ultra-rare neurodegenerative genetic disorders including AADC deficiency, GM-1 Gangliosidosis, Niemann-Pick disease types A and C, and SPG50, delivered to children worldwide.
• Target10 Program Initiative developed with Viralgen Vector Core to accelerate ten gene therapy treatments for ten ultra-rare diseases within ten years by removing manufacturing barriers for small patient population programs.
• CCF Open-Source

Quantifiable outcome

• 25+ children successfully treated with AADC gene therapy with excellent results
• +3 more outcomes

Named customers8 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core, minor and supporting.

• Viralgen Vector CorecoreStrategic or Co-development Partner · 25 February 2025Cornerstone partner for the Target10 Program - a leading manufacturer of AAV vectors providing manufacturing capacity, expertise, and significantly discounted vector production for CCF ultra-rare disease programs. Partnership enables cost savings of several million dollars per program compared to commercial costs and 12-24 months of time savings.
• University College London (UCL)coreStrategic or Co-development Partner · 1 February 2021Collaboration for Niemann Pick C preclinical studies led by Prof. Ahad Rahim. CCF provides access to Viralgen vector manufacturing and funding support for toxicology studies in partnership with UK MRC.
• CureDuchenneminorGTM or Marketing PartnerCollaboration to raise money for Ukrainian rare disease patients, specifically supporting Fundacja Parent Project Muscular Dystrophy in Gdansk, Poland providing assistance to boys with Duchenne muscular dystrophy fleeing Ukraine.
• Fundacja Parent Project Muscular DystrophysupportingStrategic or Co-development PartnerFoundation in Gdansk, Poland providing financial and medical assistance to boys with Duchenne muscular dystrophy fleeing Ukraine.
• Phoenix NestsupportingStrategic or Co-development PartnerNew York-based biotech company partnered with CCF to address Sanfilippo type C disease (Mucopolysaccharidosis III).
• CureSPG50supportingStrategic or Co-development PartnerCanadian NGO partnership to support SPG50 gene therapy development and treatment access.
• Elpida TherapeuticssupportingStrategic or Co-development PartnerPartner in SPG50 clinical trial development along with CCF, Columbus Foundation, and Viralgen Vector Core for the treatment being developed for children from Spain, Germany, and Italy.
• Interventional NeuroTherapy Center, Brodno HospitalcoreStrategic or Co-development PartnerGlobal Partner providing advanced gene therapy treatments for the world's rarest children. First Interventional Neurology Center (INC) to open in Europe and second in the world. Led by Dr. Krystof Bankiewicz, doctors perform precise operations to treat and cure children from around the world.
• Realia by JenminorGTM or Marketing PartnerJewelry artist collaboration for annual bracelets (RARE 2021, HOPE 2022) to spread awareness for ultra-rare genetic diseases and raise funds through the #ShareYourRare campaign.
• UNRLminorGTM or Marketing PartnerLimited edition merchandise partnership for 'RARE' branded hats sold to raise funds for CCF's Rare Fund.
• Ohio State UniversitycoreStrategic or Co-development PartnerHome to Dr. Krystof Bankiewicz's gene therapy program for AADC deficiency and other neurological disorders. Bankiewicz serves as Professor of Neurosurgery and Gilbert and Kathryn Mitchell Endowed Chair.
• Fundación ColumbuscoreStrategic or Co-development PartnerEuropean counterpart/sister foundation based in Valencia, Spain. Established in 2017 alongside Columbus Children’s Foundation to accelerate access to gene therapy for ultra-rare diseases in Europe.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Asklepios Biopharmaceutical (AskBio): Clinical-stage AAV gene therapy company co-founded by CCF's co-founders, acquired by Bayer for $4B in 2020. Comparable AAV gene therapy platform but operating commercially across broader indications; CCF's nonprofit model exists in part because AskBio cannot economically pursue ultra-rare pediatric indications.
• National Organization for Rare Disorders (NORD): Largest US rare disease patient advocacy organization serving as a convener, funder, and policy advocate across hundreds of indications. Operates as a broad incumbent where CCF is a focused, single-modality nonprofit.
• EveryLife Foundation for Rare Diseases: US nonprofit advancing rare disease policy, newborn screening, and patient access. Comparable as a rare-disease nonprofit but focused on regulatory/legislative advocacy rather than direct gene therapy program development.

Others

• Viralgen Vector Core: AAV contract development and manufacturing organization (CDMO) co-founded by the same principals as CCF. Included as an ecosystem enabler — Viralgen is the manufacturing backbone for most of CCF's programs and represents the closest infrastructure peer.

Emerging players

• Vivet Therapeutics: Emerging clinical-stage AAV gene therapy company developing treatments for rare metabolic and neurological diseases. Javier Garcia (CCF trustee) sits on Vivet's board, and Vivet represents the kind of small biotech that could either partner with or compete against CCF in adjacent rare disease programs.

Direct peers

• CureDuchenne: Nonprofit focused on accelerating Duchenne muscular dystrophy treatments and cures through research funding and clinical partnerships. Directly comparable as a rare-disease gene therapy nonprofit with which CCF co-runs cross-border patient support programs (Ukrainian refugee support).
• CureSPG50: Canadian nonprofit dedicated to funding SPG50 gene therapy development — one of CCF's core partners and a co-developer on the SPG50 clinical trial. Closest functional peer as a single-disease gene therapy nonprofit.
• Fundacja Parent Project Muscular Dystrophy: Polish nonprofit serving Duchenne muscular dystrophy patients, partnering with CCF and CureDuchenne to support Ukrainian refugee families. Comparable mission-driven rare disease patient support organization operating in a regional geography.
• Phoenix Nest: Early-stage biotech co-developing Sanfilippo Type C gene therapy with CCF. Comparable as a small gene therapy developer focused on a single ultra-rare pediatric indication, complementing CCF's nonprofit model.
• The Cure Sanfilippo Foundation: Parent-led nonprofit driving gene therapy development for Sanfilippo syndrome (Mucopolysaccharidosis III), directly overlapping with CCF's Phoenix Nest partnership for Sanfilippo Type C. Same ultra-rare pediatric neurodegenerative model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ColumbusChildrn
• Instagraminstagram.com/columbuschildrensfoundation
• Facebookfacebook.com/columbuschildrensfoundation
• LinkedInlinkedin.com/company/columbuschildrensfoundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Columbus Children's Foundation